Journal article
Phase II Study of Ganitumab, a Fully Human Anti–Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors
Abstract
PURPOSE: Ganitumab is a fully human monoclonal antibody against type-1 insulin-like growth factor receptor (IGF1R). An open-label phase II study was conducted to evaluate the efficacy and safety of ganitumab monotherapy in patients with metastatic Ewing family tumors (EFT) or desmoplastic small round cell tumors (DSRCT).
PATIENTS AND METHODS: Patients ≥16 years of age with relapsed or refractory EFT or DSRCT received 12 mg/kg of ganitumab every …
Authors
Tap WD; Demetri G; Barnette P; Desai J; Kavan P; Tozer R; Benedetto PW; Friberg G; Deng H; McCaffery I
Journal
Journal of Clinical Oncology, Vol. 30, No. 15, pp. 1849–1856
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2012
DOI
10.1200/jco.2011.37.2359
ISSN
0732-183X
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBone NeoplasmsDesmoplastic Small Round Cell TumorFemaleHumansIn Situ Hybridization, FluorescenceInsulin-Like Growth Factor IKaplan-Meier EstimateMaleMiddle AgedOncogene Proteins, FusionProto-Oncogene Protein c-fli-1RNA-Binding Protein EWSReceptor, IGF Type 1Sarcoma, EwingSequence Analysis, RNATime FactorsTranslocation, GeneticTreatment OutcomeYoung Adult